Loading...
XSTO
EGTX
Market cap177mUSD
Dec 05, Last price  
4.64SEK
1D
-2.52%
1Q
-10.25%
Jan 2017
-73.49%
IPO
-62.87%
Name

Egetis Therapeutics AB (publ)

Chart & Performance

D1W1MN
XSTO:EGTX chart
P/E
—
P/S
36.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.95%
Rev. gr., 5y
-11.00%
Revenues
46m
-19.97%
002,66600000013,585,00028,211,00082,562,00040,662,00038,243,00022,500,00057,600,00046,100,000
Net income
-344m
L+5.11%
-559,065-1,345,648-3,800,624-33,246,055-33,857,000-25,549,000-48,420,000-43,836,000-38,223,000-87,935,000-85,003,000-61,429,000-179,121,000-104,730,000-189,500,000-326,900,000-343,600,000
CFO
-228m
L-18.14%
-2,717,199-14,395,782-31,957,000-28,066,000-41,384,000-51,153,000-36,115,000-86,551,000-80,310,000-62,641,000-134,639,000-130,110,000-173,500,000-278,400,000-227,900,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
URL
https://www.egetis.com/
IPO date
Apr 07, 2011
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT